Quality of life should be the primary outcome for disease-modifying therapy trials in MS

Abstract

Get full access to this article

View all access options for this article.

References

Goverover

Genova

Smith

, et al. Changes in activity participation after multiple sclerosis diagnosis. Int J MS Care 2020; 22(1): 23–30.

Claflin

Broadley

Taylor

. The effect of disease modifying therapies on disability progression in multiple sclerosis: A systematic overview of meta-analyses. Front Neurol 2019; 9. https://www.frontiersin.org/articles/10.3389/fneur.2018.01150 (accessed 6 February 2023).

Scott

. Teriflunomide: A review in relapsing–remitting multiple sclerosis. Drugs 2019; 79(8): 875–886.

Day

Rae-Grant

Armstrong

, et al. Identifying priority outcomes that influence selection of disease-modifying therapies in MS. Neurol Clin Pract 2018; 8(3): 179–185.

Foley

Brandes

. Redefining functionality and treatment efficacy in multiple sclerosis. Neurology 2009; 72(23 Suppl. 5): S1–S11.

Teisberg

Wallace

O’Hara

. Defining and implementing value-based health care: A strategic framework. Acad Med 2020; 95(5): 682–685.

Gil-González

Martín-Rodríguez

Conrad

, et al. Quality of life in adults with multiple sclerosis: A systematic review. BMJ Open 2020; 10(11): e041249.

WHOQOL—Measuring Quality of Life—The World Health Organization. https://www.who.int/tools/whoqol (accessed 22 February 2023).

Vickrey

Hays

Harooni

, et al. A health-related quality of life measure for multiple sclerosis. Qual Life Res 1995; 4(3): 187–206.

10.

Kalb

Beier

Benedict

, et al. Recommendations for cognitive screening and management in multiple sclerosis care. Mult Scler 2018; 24(13): 1665–1680.

Quality of life should be the primary outcome for disease-modifying therapy trials in MS—Yes

Abstract

Get full access to this article

References